Biodesix ropes in $12M in Series E financing for blood-based lung cancer Dx

Biodesix CEO David Brunel

Biodesix reeled in an additional $12 million in Series E financing for its blood-based test for non-small cell lung cancer, bringing the company's proceeds from the sale to $27 million. The Boulder, CO-based molecular diagnostic outfit plans to use the funds to ramp up development for its VeriStrat tool, which helps oncologists decide whether to treat advanced lung cancer patients with Roche's ($RHHBY) Tarceva (erlotinib) or traditional chemotherapy. "Securing this investment enables us to effectively bring innovative diagnostics to market that help inform treatment decisions and improve patient care in a cost effective manner," CEO David Brunel said in a statement. More from FierceMedicalDevices

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.